The Chronic Lymphocytic Leukemia Channel is supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), BeOne Medicines (Silver) and Lilly (Silver).
The Community Focus Channel is supported with funding from Johnson & Johnson (Gold).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASH 2025 | Guidance for treating patients with CLL who have relapsed after initial therapy
Marc Hoffman, MD, University of Kansas Medical Center, Kansas City, KS, gives guidance for treating patients with chronic lymphocytic leukemia (CLL) who have relapsed after initial therapy. Dr Hoffman describes several clinical scenerios and his approach to treatment, which is dependent on how the patient has relapsed and which treatment they received. This interview took place at the 67th ASH Annual Meeting and Exposition, held in Orlando, FL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
